Studie

A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children,Adolescents and Young Adults with Relapsed or Refractory Osteosar

Erkrankungsgruppe:

Solide Tumore

Organsystem:

Sonstiges

Stadium:

Rückfall, Therapierefraktär

Standort:

Essen

EudraCT:

2019-003696-19

Prüfplan-Code:

E7080-G000-230

Phase:

II

Prüfsubstanz:

Lenvatinib, Ifosfamide, Etoposide

Sponsor:

Eisai Ltd., UK